FDA declares resolution of nationwide semaglutide injection shortage and outlines 60 to 90 day transition periods for compounding facilities while other GLP-1 medications remain in limited supply.
With no new FDA-approved drugs for chronic wound debridement since 1965, MediWound's phase 3 trial tests EscharEx for venous leg ulcers in 216 patients.
FDA-cleared clinical trials will assess the safety, immunogenicity, and viability of genetically modified pig kidney transplants in patients with end-stage renal disease.
Provepharm's urgent nationwide recall warns that contaminated injectable phenylephrine could lead to "serious complications such as stroke or even death" if particulate matter enters blood vessels.
2023 brought record-breaking heat waves in the United States, significantly impacting vulnerable groups. Analysis by the CDC revealed a substantial number of heat-related illness (HRI) emergency department visits, resulting in multiple public health alerts.
On November 16, 2023, the U.S. Food and Drug Administration (FDA) approved capivasertib (Truqap) with fulvestrant for adult patients with hormone receptor–positive, HER2-negative locally advanced or m...